INTRICON CORPORATION EXHIBIT 99.1 TO FORM 8-K DATED OCTOBER 24, 2007

ST. PAUL, Minn. — Oct. 24, 2007 — IntriCon Corporation (AMEX: IIN), a designer, developer, manufacturer and distributor of body-worn medical and electronics devices, today announced financial results for its 2007 third quarter ended September 30, 2007.

For the third quarter, the company reported quarterly net sales of $18.4 million, a 48 percent increase from net sales of $12.5 million for the 2006 third quarter. IntriCon delivered third-quarter net income of $650,000, or $0.12 per diluted share, up 48 percent from net income of $438,000, or $0.08 per diluted share, for the 2006 third quarter. The 2007 net sales and net income include results from the late-May 2007 acquisition of Tibbetts Industries, Inc.

“Our core businesses of medical, hearing health and professional audio—being driven by the demand for miniature body-worn devices—posted significant year-over-year gains,” said Mark S. Gorder, president and chief executive officer of IntriCon. “Medical was particularly strong, growing 137 percent year over year. In the medical arena, we’re seeing increased demand from OEMs.”

For the nine-month period, IntriCon reported net sales of $50.0 million and net income of $1.2 million, or $0.22 per diluted share. This compares to 2006 nine-month sales of $37.5 million and net income of $719,000, or $0.14 per diluted share, from continuing operations.

Included in the 2007 third-quarter results are net sales of $2.0 million and net income of $89,000, or $0.02 per diluted share, from the acquisition of Tibbetts Industries. The nine-month period includes net sales of $2.9 million and net income of $37,000, or $0.01 per diluted share, from Tibbetts Industries.

For the third quarter, IntriCon’s core businesses increased 60 percent year over year. The company’s non-core electronics business decreased 3 percent from the third quarter of 2006. IntriCon’s gross margins rose to 28 percent from 23 percent a year earlier. Operating income more than doubled.

Said Gorder, “By focusing on our expanding core businesses, we’re delivering significant incremental gains across the board. The Tibbetts acquisition enhances our medical and professional audio capabilities and product portfolio, and gives IntriCon a presence in the security market. Additionally, we recently entered into a strategic alliance with Minneapolis-based Advanced Medical Electronics Corp. (AME) to develop and manufacture new miniature, wireless, ultra low-power bio-telemetry instruments.

“Through the agreement, IntriCon will manufacture AME’s bio-telemetry devices and supply them to third-party distributors. We also gain exclusive access to key AME technology and will be able to use this technology to develop additional bio-telemetry applications. Increasingly, the medical industry is looking for wireless, low-power capabilities in their devices, and we believe that AME’s technology will allow us to develop new devices that better connect patients and care givers, providing critical information and feedback.”

Also in the third quarter, IntriCon’s Singapore facility achieved International Organization for Standardization (ISO) 13485 compliance. ISO 13485 compliance means that the company’s Singapore plant meets the comprehensive management system requirements for the design and manufacture of medical devices.

Said Gorder, “Achieving ISO 13485 compliance is a significant milestone for the company. It gives our key OEM customers a cost-effective way to manufacture their body-worn devices and other medical products. Being competitive in today’s marketplace demands the ability to have manufacturing capabilities in lower-cost geographies. Going forward, we plan to expand into other cost-efficient locations.”

In addition to possible overseas expansion, according to Gorder, IntriCon’s growth strategies may also include further acquisitions that are consistent with the company’s mission. The company continues to work to accelerate new product development, further commit to research and development initiatives, and incorporate proprietary technology in all devices.

Concluded Gorder, “As a company we’re delivering both sequential and year-over-year growth in our core businesses. While seasonality is a normal part of our industry, we believe that our long-term prospects in the miniature body-worn device arena are promising.”

Headquartered in Arden Hills, Minn., IntriCon Corporation designs, develops and manufactures miniature and micro-miniature body-worn medical and electronics products. The company is focused on four key markets: medical, hearing health, professional audio and communications, and electronics. IntriCon has facilities in the United States, Asia and Europe. The company’s common stock trades under the symbol “IIN” on the American Stock Exchange. For more information about IntriCon, visit www.intricon.com.

Statements made in this release and in IntriCon’s other public filings and releases that are not historical facts or that include forward-looking terminology such as “may”, “will”, “believe”, “expect”, “should”, “optimistic” or “continue” or the negative thereof or other variations thereon are “forward-looking statements” within the meaning of the Securities Exchange Act of 1934 as amended. These forward-looking statements include, without limitation, statements concerning the benefits AME’s technology, prospects in the miniature body-worn device arena, future growth and expansion, future financial condition and performance, prospects, and the positioning of IntriCon to compete in chosen markets. These forward-looking statements are affected by known and unknown risks, uncertainties and other factors that are beyond IntriCon’s control, and may cause IntriCon’s actual results, performance or achievements to differ materially from the results, performance and achievements expressed or implied in the forward-looking statements. These risks, uncertainties and factors include, without limitation, risks related to the Tibbetts acquisition, including unanticipated liabilities and expenses, the risk that IntriCon may not be able to achieve its long-term strategy, weakening demand for products of the company due to general economic conditions, possible non-performance of developing technological products, the volume and timing of orders received by the company, changes in the mix of products sold, competitive pricing pressures, availability of electronic components for the company’s products, ability to create and market products in a timely manner, competition by competitors with more resources than the company, foreign currency risks arising from the company’s foreign operations and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2006. The company disclaims any intent or obligation to publicly update or revise any forward-looking statements, regardless of whether new information becomes available, future developments occur or otherwise.

	Three Months Ended
	September 30, 2007			September 30, 2006
Sales, net	$	18,441,894		$	12,487,832

Costs of sales		13,316,223			9,614,058

Gross profit		5,125,671			2,873,774

Operating expenses:
Selling expense		1,094,340			848,499
General and administrative expense (a)		2,167,118			1,177,860
Research and development expense		734,778			256,678
Total operating expenses		3,996,236			2,283,037

Operating income		1,129,435			590,737

Interest expense		(278,251	)		(91,394	)
Interest income		13,265			16,842
Equity in earnings of partnerships		(75,000	)		—
Other expense, net		(53,444	)		(10,401	)

Income before income taxes		736,005			505,784
Income tax expense		85,545			52,856
Income from continuing operations		650,460			452,928

Loss from discontinued operations, net of income tax expense		—			(14,655	)

Net income	$	650,460		$	438,273


Income (loss) per share:
Basic
Continuing operations	$	.13		$	.09
Discontinued operations		—			(.01	)
	$	.13		$	.08

Diluted
Continuing operations	$	.12		$	.08
Discontinued operations		—			(.00	)
	$	.12		$	.08

Average shares outstanding:
Basic		5,201,966			5,157,925
Diluted		5,562,345			5,413,277

	Nine Months Ended
	September 30, 2007			September 30, 2006

Sales, net	$	49,958,858		$	37,532,457

Costs of sales		37,415,415			28,372,969

Gross profit		12,543,443			9,159,488

Operating expenses:
Selling expense		2,899,978			2,620,031
General and administrative expense (a)		5,200,599			3,804,666
Research and development expense		2,118,236			1,437,499
Total operating expenses		10,218,813			7,862,196

Operating income		2,324,630			1,297,292

Interest expense		(771,656	)		(392,570	)
Interest income		71,048			56,482
Equity in earnings of partnerships		(155,000	)		—
Other expense, net		(43,394	)		(71,345	)

Income before income taxes		1,425,628			889,859
Income tax expense		220,816			127,874
Income from continuing operations		1,204,812			761,985

Loss from discontinued operations, net of income tax expense		—			(42,630	)

Net income	$	1,204,812		$	719,355


Income (loss) per share:
Basic
Continuing operations	$	.23		$	.15
Discontinued operations		—			(.01	)
	$	.23		$	.14

Diluted
Continuing operations	$	.22		$	.14
Discontinued operations		—			(.01	)
	$	.22		$	.13

Average shares outstanding:
Basic		5,197,071			5,154,633
Diluted		5,466,128			5,490,606

Assets
	September 30, 2007		December 31, 2006
	(unaudited)
Current assets

Cash	$	1,022,869	$	599,459

Restricted cash		69,336		60,158

Accounts receivable, less allowance for doubtful accounts of $218,000 at 2007 and $246,000 at 2006		9,200,046		8,456,450

Inventories		10,273,165		9,030,615

Refundable income taxes		30,951		103,587

Note receivable from sale of discontinued operations, less allowance of $225,000 at 2007 and 2006		234,000		300,000

Other current assets		687,750		235,418


Total current assets		21,518,117		18,785,687

Property, plant and equipment
Machinery and equipment		36,376,488		28,767,904
Less: accumulated depreciation		28,118,423		21,994,344

Net property, plant and equipment		8,258,065		6,773,560

Long-term note receivable from sale of discontinued operations		—		75,000

Goodwill		8,147,623		5,927,181

Investment in partnerships		1,558,925		1,800,000

Other assets, net		1,454,638		920,051

	$	40,937,368	$	34,281,479

Liabilities and Shareholders’ Equity	September 30, 2007			December 31, 2006
	(unaudited)
Current liabilities

Checks written in excess of cash	$	1,381,845		$	661,756

Current maturities of long-term debt		1,195,373			952,730

Accounts payable		3,704,750			5,161,450

Income taxes payable		150,230			173,810

Deferred gain on building sale		110,084			110,084

Short-term partnership payable		260,000			260,000

Other accrued liabilities		4,060,566			3,021,201

Total current liabilities		10,862,848			10,341,031

Long-term debt, less current maturities		8,772,155			3,830,461

Other post-retirement benefit obligations		951,175			1,063,744

Long-term partnership payable		1,280,000			1,280,000

Note payable, net of current portion (Amecon)		515,720			515,720

Deferred income taxes		79,273			79,273

Accrued pension liability		584,808			628,569

Deferred gain on building sale, net of current portion		853,152			935,715

Total non-current liabilities		13,036,283			8,333,482

Total liabilities		23,899,131			18,674,513

Commitments and contingencies
Shareholders’ equity
Common shares, $1 par; 10,000,000 shares authorized;
5,722,975 and 5,706,235 shares issued; 5,207,221 and 5,190,481 outstanding		5,722,975			5,706,235
Additional paid-in capital		12,570,899			12,339,988

Accumulated earnings (deficit)		215,307			(989,505	)

Accumulated other comprehensive loss		(205,866	)		(184,674	)

Less: 515,754 common shares held in treasury, at cost		(1,265,078	)		(1,265,078	)

Total shareholders’ equity		17,038,237			15,606,966

	$	40,937,368		$	34,281,479

At IntriCon:	At Padilla Speer Beardsley:
Scott Longval, CFO	Matt Sullivan/Marian Briggs
651-604-9526	612-455-1700
slongval@intricon.com	msullivan@psbpr.com / mbriggs@psbpr.com